Bio-Techne director exercises options for 15,940 shares
The transaction report separately lists 5,559 shares delivered or withheld and multiple remaining option tranches.
Rhea-AI Filing Summary
BIO-TECHNE Corp (TECH) director Robert V. Baumgartner exercised options for 15,940 common shares on September 22, 2026, at a $25.30 exercise price. On the same date, 5,559 shares were delivered or withheld for payment of exercise price or tax liability, at a reported $72.55 per share. No Rule 10b5-1 plan is reported.
His listed remaining options include 12,500 underlying shares at a $31.26 exercise price, expiring October 26, 2027, and 3,777 underlying shares at $60.96, expiring October 30, 2035.
Positive
- None.
Negative
- None.
Insider Trade Summary
15,940 shares exercised/converted
Exercise
12 txns
Insider
BAUMGARTNER ROBERT V
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options (Right to Buy) | 15,940 | $0.00 | $0.00 |
| Exercise | Common Stock | 15,940 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 5,559 | $72.55 | $403K |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
Holdings After Transaction:
Stock Options (Right to Buy) — 51,381 contracts (Direct);
Common Stock — 56,884 shares (Direct)
Footnotes (1)
- F1. The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
Key Figures
Options exercised: 15,940 options
Exercise price: $25.30 per share
Common shares acquired: 15,940 shares
+4 more
7 metrics
Options exercised
15,940 options
September 22, 2026
Exercise price
$25.30 per share
Options exercised on September 22, 2026
Common shares acquired
15,940 shares
September 22, 2026
Shares delivered or withheld
5,559 shares
For payment of exercise price or tax liability on September 22, 2026
Reported price per share
$72.55 per share
Shares delivered or withheld on September 22, 2026
Underlying shares for remaining options
12,500 shares
Exercise price $31.26; expiration October 26, 2027
Underlying shares for remaining options
3,777 shares
Exercise price $60.96; expiration October 30, 2035
Key Terms
Stock Options (Right to Buy), exercise price, vesting
3 terms
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) exercisable for Common Stock"
exercise price financial
"at a $25.30 exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The option vests on the earlier of the one year anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When do TECH director Robert V. Baumgartner's 3,777 options vest?
The 3,777 options with a $60.96 exercise price vest on the earlier of the one-year anniversary of the grant date (October 30, 2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
